Next 10 |
2024-03-07 11:25:14 ET More on RAPT Therapeutics RAPT Therapeutics: Positive Data, But I Think They're Overvalued For Now H.C. Wainwright cuts RAPT to neutral, cites delays due to clinical hold J.P. Morgan cuts RAPT to neutral, recommends against buying dip S...
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
2024-02-23 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Greenbrook TMS Inc. (GBNH) rose 64.9% to $0.32 on volume of 109,974,769 shares PROSHARES TRUST (SQQQ) rose 3.7% to $12.36 on volume of 106,443,308 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.7% to $4.825 on volume...
2024-02-21 12:27:34 ET More on Mid-day movers & stocks. Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage Greenbrook TMS secures $1.5M in debt financing Compass Pathways and Greenbrook TMS enter into three-year research collabora...
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. ("RAPT" or "the Company") (NASDAQ:RAPT). Investors who purchased RAPT securities are encouraged to obtain additional informa...
2024-02-21 11:55:59 ET More on RAPT Therapeutics RAPT Therapeutics: Positive Data, But I Think They're Overvalued For Now RAPT stock craters after FDA puts clinical hold on dermatitis drug Evercore ISI starts RAPT at outperform, cites upcoming Phase 2b data S...
2024-02-21 10:00:32 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 4.6% to $0.7055 on volume of 174,330,167 shares PROSHARES TRUST (SQQQ) rose 2.3% to $11.92 on volume of 147,409,535 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $4.61 on volume ...
News, Short Squeeze, Breakout and More Instantly...
RAPT Therapeutics Inc. Company Name:
RAPT Stock Symbol:
NYSE Market:
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigat...
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therap...